Twenty years after the launch of Medicare Part D, access to branded medicines remains a significant challenge for many patients. New IQVIA research finds that initial rejection rates have risen substantially since 2021, with nearly half of first fill attempts rejected in 2025.

Download the fact sheet to explore how access barriers vary across therapeutic areas and what the latest data reveal about medicines selected for Medicare drug price negotiation.